Compare SITM & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SITM | CYTK |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 2019 | 2004 |
| Metric | SITM | CYTK |
|---|---|---|
| Price | $365.90 | $62.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $325.63 | $77.87 |
| AVG Volume (30 Days) | 389.8K | ★ 1.8M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $281,486,000.00 | $87,211,000.00 |
| Revenue This Year | $52.14 | $361.33 |
| Revenue Next Year | $44.15 | $65.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 59.04 | ★ 2609.26 |
| 52 Week Low | $105.40 | $29.31 |
| 52 Week High | $387.52 | $69.33 |
| Indicator | SITM | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 48.91 |
| Support Level | $357.31 | $59.56 |
| Resistance Level | $387.52 | $67.26 |
| Average True Range (ATR) | 18.94 | 2.36 |
| MACD | 6.01 | -0.67 |
| Stochastic Oscillator | 83.66 | 33.98 |
SiTime Corp is a provider of silicon timing systems solutions. The company designs develops and sell silicon timing systems solutions for different industries including automotive, infrastructure, aerospace-defense, consumer, internet of things, consumer and industrials. Its product offerings include Stratum 3E DCOCXOs, Programmable OCXOs, MHz Oscillators, 32.768 kHz Oscillators, Embedded Resonators, Precision MHz Super-TCXOs, and Ruggedized Oscillators. It sells its products around Taiwan, Hong Kong, the United States, and other regions and generates the majority of its revenue from Taiwan.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.